By Mill Chart
Last update: Nov 2, 2023
Unearth the potential of PFIZER INC (NYSE:PFE) as a dividend stock recommended by our stock screening tool. NYSE:PFE maintains a robust financial footing and delivers a sustainable dividend. We'll delve into the details below.
ChartMill assigns a proprietary Dividend Rating to each stock. The score is computed by evaluating various valuation aspects, like the yield, the history, the dividend growth and sustainability. NYSE:PFE was assigned a score of 8 for dividend:
A critical element of ChartMill's stock evaluation is the Health Rating, which spans from 0 to 10. This rating considers multiple health factors, including liquidity and solvency, both in absolute terms and relative to industry peers. NYSE:PFE has received a 5 out of 10:
ChartMill assigns a proprietary Profitability Rating to each stock. The score is computed by evaluating various profitability ratios and margins and ranges from 0 to 10. NYSE:PFE was assigned a score of 8 for profitability:
Every day, new Best Dividend stocks can be found on ChartMill in our Best Dividend screener.
Our latest full fundamental report of PFE contains the most current fundamental analsysis.
This is not investing advice! The article highlights some of the observations at the time of writing, but you should always make your own analysis and invest based on your own insights.
PFIZER INC
NYSE:PFE (4/26/2024, 7:09:35 PM)
Premarket: 25.5 +0.1 (+0.39%)25.4
+0.14 (+0.55%)
With the market presenting many vagaries, investors may take some solace in these dividend stocks to buy on the dip.
Pfizer's huge facility in Sanford produces its first FDA-approved gene therapy, which runs $3.5 million a dose.
The biotech's weight loss drug candidate could fuel a premium-laden buyout, but risks abound.
Whether or not these stocks hit analysts' price targets, they all should be attractive to investors seeking great income and solid growth.
You'll get dividends and more with these great stocks.
Passive investors pay attention! Invest in the best of the best with these seven dividend stocks for steady returns.
CNBC's Jim Cramer on Friday walked investors through next week on Wall Street.
Put your money to work by investing in these three high-quality dividend stocks.
Pfizer Inc. won US approval for its first gene therapy, expanding into a promising field of medicine that has proved to be a challenging business.
The agency greenlit the drug, which will be marketed as Beqvez, for adults with moderate to severe hemophilia B.